SCHEMBL12410979

SCHEMBL12410979

CCOC(=O)c1nccn1C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 4/20 0.43
HSD17B10 Q99714 2/20 0.43
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
FPR2 P25090 1/20 0.39
MAPK1 P28482 2/20 0.39
JMJD6 Q6NYC1 2/20 0.39
BRD4 O60885 1/20 0.38
CYP1A2 P05177 3/20 0.38
CYP3A4 P08684 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
LMNA P02545 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ABCB11 O95342 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30554004 0.88 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10OPRD1
SCHEMBL30554020 0.88 FPR2 (0.48) KDM4EALDH1A1HPGDHSD17B10FPR2
SCHEMBL30554016 0.86 ALDH1A1 (0.41) KDM4EALDH1A1HPGDHSD17B10OPRD1
SCHEMBL18083960 0.86 ALDH1A1 (0.43) KDM4EALDH1A1HPGDHSD17B10FPR2
SCHEMBL28714507 0.82 GABRA1 (0.58) KDM4EALDH1A1HPGDHSD17B10OPRD1
SCHEMBL12410983 0.81 JMJD6 (0.35) KDM4EALDH1A1MAPK1JMJD6LMNA
SCHEMBL24070239 0.80 TDP1 (0.46) ALDH1A1HPGDMAPK1JMJD6CYP3A4
SCHEMBL30554029 0.78 ALDH1A1 (0.40) KDM4EALDH1A1HPGDHSD17B10FPR2
SCHEMBL15357759 0.78 SMN1; SMN2 (0.34) OPRD1OPRK1FPR2SMN1; SMN2ADORA3
SCHEMBL1822302 0.78 ALDH1A1 (0.46) KDM4EALDH1A1HPGDHSD17B10JMJD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111187218-B Application of 1-substituted-1H-imidazole-2-carboxylic acid compound in preparation of metal beta-lactamase inhibitor 四川大学 2023-08-04 CN disclosed
CN-111253317-B 1-substituted-1H-imidazole-2-carboxylic acid compound 四川大学 2023-08-04 CN disclosed
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD KDM4E 3088/4885ALDH1A1 269/4885HPGD 299/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD KDM4E 3088/4885ALDH1A1 269/4885HPGD 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.